1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?, Pharma Intelligence

Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?, Pharma Intelligence

  • October 2019
  • 56 pages
  • ID: 5779987
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD)? market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5–44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by 2026.
Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.
The largest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase III. Therapies in mid-to-late-stage development for ADHD focus on a wide variety of targets. The majority of pipeline drugs in midto-late-stage development are administered via the oral route, with only one drug also being tested in intramuscular and subcutaneous formulations.
High-impact upcoming events for drugs in the ADHD space comprise topline Phase III trial results, pivotal efficacy study results, an expected patent expiration, and a meeting with the FDA.
The overall likelihood of approval of a Phase I ADHD asset is 12.9%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 8.8 years in the overall psychiatry space.
There have been 21 licensing and asset acquisition deals involving ADHD drugs during 2014–19. Impax Laboratories’ acquisition of certain assets related to generic products from Teva and Allergan in 2016 for $586m was the largest deal.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% in Phase III–IV, and 46% in Phase I–II.
The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 157 trials.
Takeda leads the industry sponsors with the highest number of clinical trials for ADHD, followed by Eli Lilly and Johnson and Johnson

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019’; Muscarinic Acetylcholine ...

Canavan Disease - Pipeline Review, H2 2019

Canavan Disease - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Canavan Disease - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Canavan Disease - Pipeline Review, H2 2019, provides an overview of the Canavan Disease ...

GrowthDifferentiation Factor 8 - Pipeline Review, H2 2019

GrowthDifferentiation Factor 8 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

GrowthDifferentiation Factor 8 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’GrowthDifferentiation Factor 8 - Pipeline Review, H2 2019’; Growth/Differentiation Facto ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on